Market Overview:
The global benign positional vertigo treatment market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of benign positional vertigo, rising awareness about the available treatment options, and growing demand for minimally invasive procedures. Based on type, the global benign positional vertigo treatment market is segmented into anti-histamine, anti-cholinergic, anti-depressant, and others. The anti-histamine segment is expected to account for the largest share of the market in 2018 owing to its high usage in treating various types of allergies. However, the anti-depressant segment is projected to grow at a higher CAGR during the forecast period due its ability to treat various psychological disorders associated with benign positional vertigo. Based on application,the global benign positional vertigo treatment market is divided into pediatric patients (age group 0–18 years), adult patients (age group 19–65 years), and geriatric patients (>65 years). The pediatric patient segment accounted for majority share of this market in 2017 and it is projected that this trend will continue duringthe forecast period as well because children are more susceptibleto developing BPPV owingto their immature vestibular systemand lackof balance control skills .
Product Definition:
The treatment of benign positional vertigo (BPV) is aimed at resolving the patient's symptoms. This typically involves a series of exercises that are designed to move the otoconia in the ear canals and help them to resettle in a different location. If left untreated, BPV can often lead to chronic dizziness and problems with balance.
Anti-histamine:
Anti-histamine is a medication used to reduce the symptoms of Histamine Intoxication. It works by blocking the action of histamine, a chemical that causes drowsiness and itching. Anti-histamines are used in various forms such as tablets, injections, nasal sprays and eye drops.
Anti-cholinergic:
Anti-cholinergic drugs block the action of acetylcholine, a chemical messenger that facilitates information transfer in the brain. Anti-cholinergic medication is used to treat symptoms of benign positional vertigo such as nausea and vomiting, which are caused by spinning or moving dizziness.
Application Insights:
The adults segment held the largest share of the global benign positional vertigo treatment market in 2017. This can be attributed to an increase in the prevalence of Benign Positional Vertigo (BPD) among adults. According to a study, BPD is more common among older people and affects around 5% of individuals above 60 years. In addition, another factor contributing towards a larger share for this segment is that many drugs used for children are not suitable for use in adult patients due to different drugokinetics and pharmacodynamics between child and adult population. Thus, various companies have developed drugs specifically designed for use in Benign Positioning Disorder (BPD) treatment without any side effects or adverse reactions across all age groups including pediatric, geriatric as well as adult patients suffering from BPDs at home or hospital settings without medical consultation or diagnosis by using machine learning algorithms based on data collected from clinical trials studies conducted thus far.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the high prevalence of Benign Positional Vertigo (BPP) and its treatment, availability of highly advanced healthcare infrastructure, and rising consumer awareness about various treatment options. In addition, increasing government initiatives for raising awareness about BPP is also expected to drive regional growth over the forecast period. For instance, The American Academy of Neurology (AAN), released a Practice Guideline that provides recommendations regarding diagnosis and management of BPP in adults and children that includes screening questionnaires for all patients aged 6 months or older who present with dizziness or spinning sensation accompanied by nausea or vomiting.
Growth Factors:
- Increasing incidence of vertigo: The global incidence of vertigo is increasing at a significant rate. This is primarily attributed to the changing lifestyle and dietary habits, which are leading to various health problems such as obesity, diabetes, and hypertension. Benign positional vertigo (BPV) is one of the most common types of vertigo, affecting nearly 30% of the population at some point in their lives. Thus, there is a growing demand for effective BPV treatments.
- Growing awareness about BPV: There is a growing awareness among people about benign positional vertigo and its symptoms. This has led to an increase in the number of people seeking treatment for this condition.
- Technological advancements: The field of medicine is constantly evolving with new technological advancements being made every day. This has led to the development of novel and more effective treatments for benign positional vertigo that are safe and easy to use..
Scope Of The Report
Report Attributes
Report Details
Report Title
Benign Positional Vertigo Treatment Market Research Report
By Type
Anti-histamine, Anti-cholinergic, Anti-depressant, Others
By Application
Pediatrics, Adults, Geriatrics
By Companies
Pfizer, Sanofi, Medichem, LGM Pharma, AstraZeneca, Intas Pharmaceutical, Cadila Pharmaceuticals, Sun Pharmaceutical Industries, Marclabs
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
130
Number of Tables & Figures
91
Customization Available
Yes, the report can be customized as per your need.
Global Benign Positional Vertigo Treatment Market Report Segments:
The global Benign Positional Vertigo Treatment market is segmented on the basis of:
Types
Anti-histamine, Anti-cholinergic, Anti-depressant, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pediatrics, Adults, Geriatrics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Sanofi
- Medichem
- LGM Pharma
- AstraZeneca
- Intas Pharmaceutical
- Cadila Pharmaceuticals
- Sun Pharmaceutical Industries
- Marclabs
Highlights of The Benign Positional Vertigo Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-histamine
- Anti-cholinergic
- Anti-depressant
- Others
- By Application:
- Pediatrics
- Adults
- Geriatrics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Benign Positional Vertigo Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Benign positional vertigo (BV) is a condition that affects the balance system in the inner ear. Symptoms can include dizziness, nausea, and vomiting. Treatment typically includes medication and/or surgery to correct the imbalance in the balance system.
Some of the major companies in the benign positional vertigo treatment market are Pfizer, Sanofi, Medichem, LGM Pharma, AstraZeneca, Intas Pharmaceutical, Cadila Pharmaceuticals, Sun Pharmaceutical Industries, Marclabs.
The benign positional vertigo treatment market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Benign Positional Vertigo Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Benign Positional Vertigo Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Benign Positional Vertigo Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Benign Positional Vertigo Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Benign Positional Vertigo Treatment Market Size & Forecast, 2018-2028
4.5.1 Benign Positional Vertigo Treatment Market Size and Y-o-Y Growth
4.5.2 Benign Positional Vertigo Treatment Market Absolute $ Opportunity
Chapter 5 Global Benign Positional Vertigo Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Benign Positional Vertigo Treatment Market Size Forecast by Type
5.2.1 Anti-histamine
5.2.2 Anti-cholinergic
5.2.3 Anti-depressant
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Benign Positional Vertigo Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Benign Positional Vertigo Treatment Market Size Forecast by Applications
6.2.1 Pediatrics
6.2.2 Adults
6.2.3 Geriatrics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Benign Positional Vertigo Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Benign Positional Vertigo Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Benign Positional Vertigo Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Benign Positional Vertigo Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Benign Positional Vertigo Treatment Market Size Forecast by Type
9.6.1 Anti-histamine
9.6.2 Anti-cholinergic
9.6.3 Anti-depressant
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Benign Positional Vertigo Treatment Market Size Forecast by Applications
9.10.1 Pediatrics
9.10.2 Adults
9.10.3 Geriatrics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Benign Positional Vertigo Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Benign Positional Vertigo Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Benign Positional Vertigo Treatment Market Size Forecast by Type
10.6.1 Anti-histamine
10.6.2 Anti-cholinergic
10.6.3 Anti-depressant
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Benign Positional Vertigo Treatment Market Size Forecast by Applications
10.10.1 Pediatrics
10.10.2 Adults
10.10.3 Geriatrics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Benign Positional Vertigo Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Benign Positional Vertigo Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Benign Positional Vertigo Treatment Market Size Forecast by Type
11.6.1 Anti-histamine
11.6.2 Anti-cholinergic
11.6.3 Anti-depressant
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Benign Positional Vertigo Treatment Market Size Forecast by Applications
11.10.1 Pediatrics
11.10.2 Adults
11.10.3 Geriatrics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Benign Positional Vertigo Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Benign Positional Vertigo Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Benign Positional Vertigo Treatment Market Size Forecast by Type
12.6.1 Anti-histamine
12.6.2 Anti-cholinergic
12.6.3 Anti-depressant
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Benign Positional Vertigo Treatment Market Size Forecast by Applications
12.10.1 Pediatrics
12.10.2 Adults
12.10.3 Geriatrics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Benign Positional Vertigo Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Benign Positional Vertigo Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Benign Positional Vertigo Treatment Market Size Forecast by Type
13.6.1 Anti-histamine
13.6.2 Anti-cholinergic
13.6.3 Anti-depressant
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Benign Positional Vertigo Treatment Market Size Forecast by Applications
13.10.1 Pediatrics
13.10.2 Adults
13.10.3 Geriatrics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Benign Positional Vertigo Treatment Market: Competitive Dashboard
14.2 Global Benign Positional Vertigo Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Sanofi
14.3.3 Medichem
14.3.4 LGM Pharma
14.3.5 AstraZeneca
14.3.6 Intas Pharmaceutical
14.3.7 Cadila Pharmaceuticals
14.3.8 Sun Pharmaceutical Industries
14.3.9 Marclabs
